drugset

Drugs / Atipamezole

Follow last change May 2026 re-read 2 minutes ago

Atipamezole

also known as 4-(2-ethyl-2-indanyl)imidazole. · Antisedan · Atipamezol · MPV-1248

Investigated by: Orion Corporation, Orion Pharma · University of Turku

Trials 1 · a red edge is where a trial was stopped

today NCT01435213 · Ph 1

2012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT01435213	Sep 2011 → Jan 2012	—	University of Turku	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04942340 Comparator	May 2023 → Apr 2026	—	University of Chicago	Withdrawn	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Atipamezole	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04942340 ↗ 1 NCT01435213 ↗
Known as	4-(2-ethyl-2-indanyl)imidazole.	ChEMBL registry synonym — accepted as the source's own label CHEMBL353972 ↗
Known as	Antisedan	ChEMBL registry synonym — accepted as the source's own label CHEMBL353972 ↗
Known as	Atipamezol	ChEMBL registry synonym — accepted as the source's own label CHEMBL353972 ↗
Known as	MPV-1248	ChEMBL registry synonym — accepted as the source's own label CHEMBL353972 ↗
Modality	Small molecule	— CHEMBL353972 ↗
Route	Intravenous	“as an intravenous infusion” NCT01435213 ↗